KALA BIO, INC. Operating Expenses
KALA BIO, INC. (KALA) reported Operating Expenses of $1.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-19
- KALA BIO, INC. operating expenses for the quarter ending 2026-06-30 was $1.72M, a 84.39% decline year-over-year.
- KALA BIO, INC. operating expenses for the quarter ending 2026-03-31 was $1.80M, a 83.11% decline year-over-year.
- KALA BIO, INC. operating expenses for the quarter ending 2025-12-31 was $10.22M, a 8.10% increase year-over-year.
- KALA BIO, INC. operating expenses for the quarter ending 2025-09-30 was $7.24M, a 27.52% decline year-over-year.
- KALA BIO, INC. operating expenses for fiscal 2025 was $39.16M, a 4.45% decline from fiscal 2024.
- KALA BIO, INC. operating expenses for fiscal 2024 was $40.98M, a 3.33% increase from fiscal 2023.
- KALA BIO, INC. operating expenses for fiscal 2023 was $39.66M, a 53.66% decline from fiscal 2022.
- KALA BIO, INC. operating expenses for fiscal 2022 was $85.60M, a 39.50% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-19 | $3.52M 10-Q · filed 2026-08-19 | $13.75M derived: sum of 3 quarters · filed 2026-08-19 | $20.99M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-15 | $12.03M derived: sum of 2 quarters · filed 2026-05-15 | $19.27M derived: sum of 3 quarters · filed 2026-05-15 | $30.29M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $17.46M derived: sum of 2 quarters · filed 2026-04-15 | $28.49M derived: sum of 3 quarters · filed 2026-08-19 | $39.16M 10-K · filed 2026-04-15 |
| 2025-09-30 | $7.24M 10-Q · filed 2025-11-19 | $18.27M derived: sum of 2 quarters · filed 2026-08-19 | $28.94M 10-Q · filed 2025-11-19 | $38.40M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $11.03M 10-Q · filed 2026-08-19 | $21.70M 10-Q · filed 2026-08-19 | $31.16M derived: sum of 3 quarters · filed 2026-08-19 | $41.14M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $10.67M 10-Q · filed 2026-05-15 | $20.13M derived: sum of 2 quarters · filed 2026-05-15 | $30.12M derived: sum of 3 quarters · filed 2026-05-15 | $39.72M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $9.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $19.45M derived: sum of 2 quarters · filed 2026-04-15 | $29.05M derived: sum of 3 quarters · filed 2026-04-15 | $40.98M 10-K · filed 2026-04-15 |
| 2024-09-30 | $9.99M 10-Q · filed 2025-11-19 | $19.59M derived: sum of 2 quarters · filed 2025-11-19 | $31.52M 10-Q · filed 2025-11-19 | $41.14M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $9.61M 10-Q · filed 2025-08-08 | $21.54M 10-Q · filed 2025-08-08 | $31.16M derived: sum of 3 quarters · filed 2025-08-08 | $39.92M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $11.93M 10-Q · filed 2025-05-14 | $21.55M derived: sum of 2 quarters · filed 2025-05-14 | $30.31M derived: sum of 3 quarters · filed 2025-05-14 | $39.91M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $9.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $18.38M derived: sum of 2 quarters · filed 2025-03-31 | $27.98M derived: sum of 3 quarters · filed 2025-03-31 | $39.66M 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.76M 10-Q · filed 2024-11-12 | $18.36M derived: sum of 2 quarters · filed 2024-11-12 | $30.04M 10-Q · filed 2024-11-12 | $40.30M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $9.60M 10-Q · filed 2024-08-06 | $21.28M 10-Q · filed 2024-08-06 | $31.53M derived: sum of 3 quarters · filed 2024-08-06 | $46.52M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $11.68M 10-Q · filed 2024-05-14 | $21.93M derived: sum of 2 quarters · filed 2024-05-14 | $36.92M derived: sum of 3 quarters · filed 2024-05-14 | $65.00M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $10.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $25.24M derived: sum of 2 quarters · filed 2024-03-29 | $53.31M derived: sum of 3 quarters · filed 2024-03-29 | $85.60M 10-K · filed 2024-03-29 |
| 2022-09-30 | $14.99M 10-Q · filed 2023-11-13 | $43.06M derived: sum of 2 quarters · filed 2023-11-13 | $75.35M 10-Q · filed 2023-11-13 | $124.02M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $28.07M 10-Q · filed 2023-08-04 | $60.36M 10-Q · filed 2023-08-04 | $109.03M derived: sum of 3 quarters · filed 2023-08-04 | $138.17M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $32.29M 10-Q · filed 2023-05-09 | $80.96M derived: sum of 2 quarters · filed 2023-05-09 | $110.09M derived: sum of 3 quarters · filed 2023-05-09 | $142.19M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $48.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $77.81M derived: sum of 2 quarters · filed 2023-03-03 | $109.91M derived: sum of 3 quarters · filed 2023-03-03 | $141.49M 10-K · filed 2023-03-03 |
| 2021-09-30 | $29.14M 10-Q · filed 2022-11-08 | $61.23M derived: sum of 2 quarters · filed 2022-11-08 | $92.81M 10-Q · filed 2022-11-08 | $124.04M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $32.10M 10-Q · filed 2022-08-11 | $63.68M 10-Q · filed 2022-08-11 | $94.90M derived: sum of 3 quarters · filed 2022-08-11 | $122.96M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $31.58M 10-Q · filed 2022-05-16 | $62.80M derived: sum of 2 quarters · filed 2022-05-16 | $90.86M derived: sum of 3 quarters · filed 2022-05-16 | $112.98M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $31.22M 10-K · filed 2021-02-25 | $59.28M derived: sum of 2 quarters · filed 2021-11-15 | $81.40M derived: sum of 3 quarters · filed 2021-11-15 | $102.59M 10-K · filed 2022-03-29 |
| 2020-09-30 | $28.06M 10-Q · filed 2021-11-15 | $50.17M derived: sum of 2 quarters · filed 2021-11-15 | $71.37M 10-Q · filed 2021-11-15 | $92.75M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $22.11M 10-Q · filed 2021-08-05 | $43.31M 10-Q · filed 2021-08-05 | $64.69M derived: sum of 3 quarters · filed 2021-08-05 | $87.70M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $21.20M 10-Q · filed 2021-05-05 | $42.57M derived: sum of 2 quarters · filed 2021-05-05 | $65.59M derived: sum of 3 quarters · filed 2021-05-05 | $90.06M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $21.38M 10-K · filed 2021-02-25 | $44.40M derived: sum of 2 quarters · filed 2021-02-25 | $68.86M derived: sum of 3 quarters · filed 2021-02-25 | $94.30M 10-K · filed 2021-02-25 |
| 2019-09-30 | $23.02M 10-K · filed 2021-02-25 | $47.48M derived: sum of 2 quarters · filed 2021-02-25 | $72.92M 10-Q · filed 2020-11-05 | $96.49M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $24.47M 10-K · filed 2021-02-25 | $49.90M 10-Q · filed 2020-08-06 | $73.47M derived: sum of 3 quarters · filed 2021-02-25 | $88.97M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $25.44M 10-K · filed 2021-02-25 | $49.00M derived: sum of 2 quarters · filed 2021-02-25 | $64.50M derived: sum of 3 quarters · filed 2021-02-25 | $79.02M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $23.57M 10-K · filed 2020-02-12 | $39.06M derived: sum of 2 quarters · filed 2020-02-12 | $53.58M derived: sum of 3 quarters · filed 2020-02-12 | $64.72M 10-K · filed 2020-02-12 |
| 2018-09-30 | $15.50M 10-K · filed 2020-02-12 | $30.02M derived: sum of 2 quarters · filed 2020-02-12 | $41.15M 10-Q · filed 2019-11-07 | $52.29M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $14.52M 10-K · filed 2020-02-12 | $25.66M 10-Q · filed 2019-08-06 | $36.80M derived: sum of 3 quarters · filed 2020-02-12 | $46.33M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $11.14M 10-K · filed 2020-02-12 | $22.28M derived: sum of 2 quarters · filed 2020-02-12 | $31.81M derived: sum of 3 quarters · filed 2020-02-12 | $41.44M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $11.14M 10-K · filed 2019-03-12 | $20.67M derived: sum of 2 quarters · filed 2019-03-12 | $30.30M derived: sum of 3 quarters · filed 2019-03-12 | $39.88M 10-K · filed 2019-03-12 |
| 2017-09-30 | $9.53M 10-K · filed 2019-03-12 | $19.16M derived: sum of 2 quarters · filed 2019-03-12 | $28.73M 10-Q · filed 2018-11-08 | $36.93M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $9.63M 10-K · filed 2019-03-12 | $19.20M 10-Q · filed 2018-08-09 | $27.40M derived: sum of 3 quarters · filed 2019-03-12 | $37.14M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $9.57M 10-K · filed 2019-03-12 | $17.77M derived: sum of 2 quarters · filed 2019-03-12 | $27.51M derived: sum of 3 quarters · filed 2019-03-12 | $37.16M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $8.20M 10-K · filed 2018-04-02 | $17.94M derived: sum of 2 quarters · filed 2018-04-02 | $27.59M derived: sum of 3 quarters · filed 2018-04-02 | $32.67M 10-K · filed 2018-04-02 |
| 2016-09-30 | $9.75M 10-K · filed 2018-04-02 | $19.40M derived: sum of 2 quarters · filed 2018-04-02 | $24.47M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $9.65M 10-K · filed 2018-04-02 | $14.73M 10-Q · filed 2017-08-31 | ||
| 2016-03-31 | $5.08M 10-K · filed 2018-04-02 | |||
| 2015-12-31 | $15.99M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |